D. Sinha

发表

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

J. Shah, M. Dimopoulos, S. Jagannath, 2021, Journal of Hematology & Oncology.

Brain Tumor Management Amidst COVID-19 Pandemic

Richa Madhawi, R. Singh, R. Prasad, 2020 .

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

M. Dimopoulos, S. Jagannath, P. Richardson, 2021, American journal of hematology.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

M. Dimopoulos, S. Jagannath, P. Richardson, 2020, The Lancet.

Genomic Pattern of GSTM1 and T1 Gene Null polymorphism of Head and Neck Cancer Patients in Eastern India

R. Shekhar, D. Sinha, Santosh Kumar, 2022, Asian Pacific journal of cancer prevention : APJCP.

To Evaluate the Incidence of ER, PR and Her2/Neu Status in Newly Diagnosed Breast Cancer Patients at a Tertiary Care Centre

A. Kumari, Sangeeta Pankaj, D. Sinha, 2018, Indian Journal of Gynecologic Oncology.

Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

M. Dimopoulos, P. Richardson, R. Benjamin, 2021, American journal of hematology.

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

J. Shah, M. Dimopoulos, S. Jagannath, 2021, American journal of hematology.

Hepatitis B in hepatocellular carcinoma patients and its correlation with alpha-fetoprotein and liver enzymes

R. Shekhar, U. Kumar, S. Singh, 2022, Journal of cancer research and therapeutics.

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer

P. Prakash, S. Sinha, R. Singh, 2022, World journal of gastrointestinal surgery.

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

S. Jagannath, P. Richardson, R. Benjamin, 2021, Blood.

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

M. Dimopoulos, S. Jagannath, Xiwen Ma, 2021, American journal of hematology.

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

M. Dimopoulos, P. Richardson, R. Hájek, 2020 .

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

M. Dimopoulos, S. Jagannath, P. Richardson, 2021, Blood.